Aligos Therapeutics (ALGS) Competitors $7.91 -0.09 (-1.13%) Closing price 04:00 PM EasternExtended Trading$7.90 0.00 (-0.06%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. RAPT, MDWD, TLSA, ELDN, DMAC, YMAB, NLTX, CRBU, FDMT, and ALMSShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Rapt Therapeutics (RAPT), MediWound (MDWD), Tiziana Life Sciences (TLSA), Eledon Pharmaceuticals (ELDN), DiaMedica Therapeutics (DMAC), Y-mAbs Therapeutics (YMAB), Neoleukin Therapeutics (NLTX), Caribou Biosciences (CRBU), 4D Molecular Therapeutics (FDMT), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Rapt Therapeutics MediWound Tiziana Life Sciences Eledon Pharmaceuticals DiaMedica Therapeutics Y-mAbs Therapeutics Neoleukin Therapeutics Caribou Biosciences 4D Molecular Therapeutics Alumis Rapt Therapeutics (NASDAQ:RAPT) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk. Do analysts rate RAPT or ALGS? Rapt Therapeutics currently has a consensus target price of $20.57, indicating a potential upside of 103.68%. Aligos Therapeutics has a consensus target price of $70.00, indicating a potential upside of 784.96%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.57Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, RAPT or ALGS? Rapt Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500. Do insiders & institutionals believe in RAPT or ALGS? 99.1% of Rapt Therapeutics shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 6.6% of Rapt Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor RAPT or ALGS? In the previous week, Rapt Therapeutics had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 6 mentions for Rapt Therapeutics and 4 mentions for Aligos Therapeutics. Rapt Therapeutics' average media sentiment score of 0.51 beat Aligos Therapeutics' score of 0.39 indicating that Rapt Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapt Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RAPT or ALGS more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,628.75%. Aligos Therapeutics' return on equity of 14.67% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -81.47% -70.24% Aligos Therapeutics -1,628.75%14.67%7.19% Which has stronger earnings and valuation, RAPT or ALGS? Rapt Therapeutics has higher earnings, but lower revenue than Aligos Therapeutics. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt Therapeutics$1.53M109.19-$129.87M-$19.20-0.53Aligos Therapeutics$3.94M12.27-$131.21M-$17.51-0.45 SummaryRapt Therapeutics beats Aligos Therapeutics on 9 of the 16 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.91M$3.07B$5.59B$9.54BDividend YieldN/A2.41%4.73%4.13%P/E RatioN/A6.2119.1622.30Price / Sales12.27314.01445.9598.89Price / CashN/A42.6035.6858.35Price / Book-1.057.828.165.60Net Income-$131.21M-$54.52M$3.25B$265.26M7 Day Performance-1.62%2.07%0.45%-1.00%1 Month Performance-0.50%17.29%8.27%6.09%1 Year Performance-31.19%14.95%30.29%23.81% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.2735 of 5 stars$7.91-1.1%$70.00+785.0%-34.0%$48.91M$3.94M0.0090Upcoming EarningsGap DownRAPTRapt Therapeutics4.0363 of 5 stars$12.67-4.8%$21.67+71.0%-54.6%$220.09MN/A-0.6680Upcoming EarningsMDWDMediWound2.2164 of 5 stars$19.93-2.0%$32.25+61.8%+5.1%$219.72M$20.22M-9.5480News CoverageTLSATiziana Life Sciences0.8773 of 5 stars$1.95+4.8%N/A+142.7%$217.34MN/A0.008ELDNEledon Pharmaceuticals1.6881 of 5 stars$3.23-10.8%$10.00+209.6%+17.8%$216.77MN/A-1.5410High Trading VolumeDMACDiaMedica Therapeutics1.2319 of 5 stars$5.06+0.2%$10.75+112.5%+31.7%$216.56MN/A-7.9120Upcoming EarningsYMABY-mAbs Therapeutics2.1686 of 5 stars$4.88+2.3%$15.60+219.7%-63.5%$216M$87.68M-7.63150News CoverageUpcoming EarningsAnalyst ForecastGap UpTrading HaltedNLTXNeoleukin TherapeuticsN/A$22.72-0.4%N/A-44.9%$213.52MN/A-7.3190CRBUCaribou Biosciences2.4537 of 5 stars$2.29+0.4%$8.50+271.2%-1.4%$212.05M$9.99M-1.41100FDMT4D Molecular Therapeutics2.5411 of 5 stars$4.64+1.5%$29.56+537.0%-67.4%$211.70M$40K-1.46120News CoverageUpcoming EarningsALMSAlumis2.5785 of 5 stars$4.04+4.1%$19.80+390.1%-68.5%$211.09MN/A0.00N/AUpcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Rapt Therapeutics Competitors MediWound Competitors Tiziana Life Sciences Competitors Eledon Pharmaceuticals Competitors DiaMedica Therapeutics Competitors Y-mAbs Therapeutics Competitors Neoleukin Therapeutics Competitors Caribou Biosciences Competitors 4D Molecular Therapeutics Competitors Alumis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALGS Stock Alerts